Newer medical therapies for metastatic soft tissue sarcoma.

about

Molecular profiling of sarcomas: new vistas for precision medicine.

P2860

Q39406356-5AC1EEA9-0813-4B04-BD01-9D747476945B

P2860

Newer medical therapies for metastatic soft tissue sarcoma.

Item

http://www.wikidata.org/entity/Q39012067

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Newer medical therapies for metastatic soft tissue sarcoma.

@en

Newer medical therapies for metastatic soft tissue sarcoma.

@nl

type

Item

label

Newer medical therapies for metastatic soft tissue sarcoma.

@en

Newer medical therapies for metastatic soft tissue sarcoma.

@nl

prefLabel

Newer medical therapies for metastatic soft tissue sarcoma.

@en

Newer medical therapies for metastatic soft tissue sarcoma.

@nl

P1476

Newer medical therapies for metastatic soft tissue sarcoma.

@en

P2093

Akash Tiwari

http://www.w3.org/2001/XMLSchema#string

Sameer Bakhshi

http://www.w3.org/2001/XMLSchema#string

Vineet Govinda Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

P304

257-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1285229

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28103739

http://www.w3.org/2001/XMLSchema#string

Newer medical therapies for metastatic soft tissue sarcoma.

about

P2860

P2860

Newer medical therapies for metastatic soft tissue sarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698